Michael Kauffman, M.D., Ph.D.
Dr Michael Kauffman was the cofounding CEO of Karyopharm Therapeutics and is currently Senior Clinical Advisor and a member of the Board of Directors of the Company. Previously, he was the Chief Medical Officer of Onyx Pharmaceuticals Inc, where he was a key leader in the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor approved in refractory myeloma. Dr Kauffman was Chairman of Proteolix (now Onyx) prior to becoming CMO, and is past President and Chief Executive Officer of EPIX Pharmaceuticals, Inc (previously Predix Pharmaceuticals, Inc). He played a key role in the Velcade® Development Program at Millennium Pharmaceuticals, and held a number of senior positions at Millennium Predictive Medicine and Biogen. Dr Kauffman received his MD and PhD from Johns Hopkins Medical School and is board certified in internal medicine.